In leukemias and gliomas, IDH mutations occur early in tumorigenesis5,8,9,23 and appear insufficient in driving tumor growth alone unless paired with ATRX loss24,25 and TP53 mutation25, or loss of 1p/19q. The gene discussed is IDH2; the disease is central nervous system cancer.